CDX2 and head and neck squamous cell carcinoma: Another study also confirms that CDX2/p300 enhances NK cell-mediated immunotherapy against head and neck squamous cell carcinoma in vitro; the findings indicate that CDX2 stimulated NK cell migration, cytotoxicity and infiltration by upregulating CXCL14 in HNSCC tissues [295].